The current practice of designing single-arm phase II survival trials is limited under the exponential model. Trial design under the exponential model may not be appropriate when a portion of patients are cured. There is no literature available for designing single-arm phase II trials under the parametric cure model. In this article, a test statistic is proposed, and a sample size formula is derived for designing single-arm phase II trials under a class of parametric cure models. Extensive simulations showed that the proposed test and sample size formula perform very well under different scenarios.
Introduction
The treatment of cancer has progressed dramatically in recent decades. It is not uncommon to see a significant proportion of patients with various types of cancers, e.g. breast cancer, non-Hodgkins lymphoma, leukemia, prostate cancer, melanoma, and head and neck cancer, being cured or surviving long term [1] . Traditional survival methods, such as the Cox model, may not be valid when there exists a proportion of patients who are cured. Thus, to adequately account for cured patients in survival data from cancer clinical trials, cure models are becoming increasingly useful. Various parametric and semiparametric cure models have been proposed by Farewell [2] , Peng et al. [3] and Kuk and Chen [4] , etc. A maximum-likelihood EM algorithm for parametric and semiparametric cure models has been proposed by Peng and Dear [5] and Sy and Taylor [6] . A SAS macro PSPMCM developed by Corbiere and Joly [7] is available to fit both parametric and semiparametric cure models.
The traditional methods for survival trial design may not be appropriate when there exists a cure rate. Sample size calculations for cure models have been developed, mainly for randomized phase III trials. For example, Halpern and Brown [8] developed a computer program to calculate the power and sample size for the exponential cure models based on Monte Carlo simulation. Ewell and Ibrahim [1] derived a power formula by considering a general alternative that allows for treatment effects on both the short and long-term survival. Recently, Wang et al. [9] derived a sample size formula under the proportional hazards cure model. However, there is no method available to design a single-arm phase II trial under the cure models. In this paper, a one-sample test statistic is introduced for the purpose of designing single-arm phase II trials under the parametric cure models. The proposed test statistic can be used to detect improvement of the cure rate, short-term survival or both.
The rest of the paper is organized as follows. The parametric cure models are introduced in Section 2. In Section 3, a one-sample test statistic is proposed. A sample size formula is derived in Section 4. Simulation studies are conducted to study the performance of the proposed test in Section 5. An example is given in Section 6 to illustrate the trial design by using the proposed method. Concluding remarks are made in Section 7.
Cure Models
The failure time, T * , is assumed to be T * = υT + (1 − υ)∞, where υ is an indicator of whether a subject will eventually (υ = 1) or never (υ = 0) experience the failure, and T denotes the failure time if the subject is not cured, with a survival distribution S(t), which is the conditional distribution for patients who will experience the failure, often called the latency distribution. Thus, the marginal survival distribution of T * is a mixture model of a cure rate π = P(υ = 0) and a latency distribution S(t) given by (1) Let λ * (t) and Λ * (t) be the hazard and cumulative hazard functions of T * and λ(t) be the hazard function of T, then we have the following relation for the hazard functions: (2) and for the cumulative hazard function (3) A simple and popular parametric cure model is the exponential cure model (4) which can be fully specified by the cure rate π and hazard rate λ for short-term survival. Suppose the historical survival data from previous trials for a certain type of disease follow the exponential cure model (4) with a cure rate of π 0 and a hazard rate of λ 0 . We want to design a study to determine whether the new treatment improves the cure rate π, the hazard rate λ or both. Specifically, we want to test the following null hypothesis: (5) against various alternative hypotheses of interest: H 1a : improvements are in the short-term survival but not in the cure rate; H 1b : improvements are in the cure rate but not in the shortterm survival; H 1c : improvements are in both the cure rate and short-term survival. Specifically, these alternative hypotheses can be formulated as (6) (7) (8) where the cure rate and hazard rate under the alternative are π 1 and λ 1 , respectively, with π 1 > π 0 and λ 1 < λ 0 .
Among the parametric models, the Weibull, Log-normal, and Log-logistic distributions are widely used in the parametric cure model analysis [10] . These survival distribution functions are as follows: 1) Weibull S(t) = e −λt κ ; 2) Log-normal ; 3) Loglogistic , with a shape parameter κ and a scale parameter λ. In this article, we will consider the study design for a single-arm phase II trial under the mixture model (1), with the latency distribution being one of these three distributions. In the design stage, we assume that the shape parameter κ can be estimated from historical data; thus, it is assumed to be known. Then the latency distribution S(t) is fully specified by the scale parameter λ or equivalently by the survival probability at a landmark time point x. Specifically, let S 0 (x) and S 1 (x) be the survival probability at a landmark time point x under the null and alternative hypotheses, thus, the hypotheses of (5-8) are equivalent to the following null hypothesis: (9) against one of the following three alternative hypotheses: (10) (11) (12) In general, let S * (t) = π + (1 − π)S(t) be the marginal survival distribution of a new study, where the latency distribution S(t) is one of the three distributions. Suppose that the cure rate and latency distribution for the historical data are π 0 and S 0 (t), respectively, then the above hypotheses (5) (6) (7) (8) or (9) (10) (11) (12) are equivalent to the following null hypothesis: (13) where , i = 0, 1, π 1 ≥ π 0 and S 1 (t) ≥ S 0 (t), with at least one of the inequalities being strictly greater than.
Test Statistics
To test the hypothesis (13), we can use a one-sample test introduced briefly in this section [11] . Suppose during the accrual phase of the trial, n subjects are enrolled in the study. Let and C i denote, respectively, the failure time and censoring time of the i th subject, where the failure time follows the mixture cure model given in equation (1) . We assume that the failure time and censoring time C i are independent and { , C i , i = 1,…, n} are independent and identically distributed. Then the observed failure time and failure indicator are and , respectively, for the i th subject. On the basis of the observed data {X i , Δ i , i = 1,⋯, n}, we define as the observed number of failures, and as the expected number of failures (asymptotically), where is the cumulative hazard of under the null hypothesis (13) . Then the one-sample test is defined by [11] (14) To study the asymptotic distribution of the one-sample test statistic, we formulate it using counting-process notations. Specifically, let N i (t) = Δ i I{X i ≤ t} and Y i (t) = I{X i ≥ t} be the failure and at-risk processes, respectively. Then Thus, the counting-process formulation of the one-sample test is given by L = W/σ, where and As shown in the Appendix 1, the exact mean of W under the null E H 0 (W) is zero and σ̂2 is an consistent estimate of Var H 0 (W). Therefore, by counting process central limit theorem [12] , under the null hypothesis, L is asymptotically standard normal distributed. Hence, we reject the null hypothesis H 0 with one-sided type I error α if L = W/σ̂ < −z 1−α , where z 1−α is the 100(1 − α) percentile of the standard normal distribution.
Sample Size Calculation
To design the study, we must calculate the sample size to detect a specified survival difference at the alternative , given the type I error α and power 1 − β. For the sample size calculation, the exact variance of W under the alternative has been derived by Wu [13] . Let the exact mean and variance of W at the alternative be and Var H 1 (W) = σ 2 , respectively, where ω and σ 2 are given below. By counting process central limit theorem, is asymptotically standard normal distributed under H 1 .
As shown in equations (A7) and (A8) in the Appendix 1, under the alternative σ̂2 → σ̄2 = (υ 1 + υ 0 )/2 and , thus, the power of the test L = W/σ̂2 satisfies the following equations:
Therefore, the required sample size for the test statistic L is given by (15) where ω = υ 1 − υ 0 , σ̄2 = (υ 1 +υ 0 )/2, and , with υ 0 , υ 1 , υ 00 , and υ 01 given as follows (see Appendix 1 equations (A3)-(A6)):
and G(t) is the survival function of censoring time C.
To calculate the quantities υ 0 , υ 1 , υ 00 , and υ 01 , we assumed that subjects were recruited with a uniform distribution over the accrual period t a and were followed for a period of t f , and no loss to follow-up. Thus, the censoring distribution is a uniform distribution on [t f , t a + t f ]. Then for a parametric cure model in which the cure rate and scale parameter are determined by the null and alternative as described above, the quantities υ 0 , υ 1 , υ 00 , and υ 01 can be calculated by numeric integrations, e.g. using R function integrate. For example, for the exponential cure model, where τ = t a + t f ; and Therefore, the study design can be conducted by calculating the sample size using formula (15).
Simulation Studies
To study the performance of the one-sample test under various parametric cure models, including the Weibull, Log-normal and Log-logistic distributions, we calculated sample sizes for each of these distributions under various design scenarios. Simulation studies were conducted to study the accuracy of the sample size estimation and performance of the onesample test under small sample size. Under each of these distributions, the shape parameter was set to κ=0.5, 1, and 2 reflecting the different types of hazard functions. Instead of specifying the scale parameter λ equivalently, we specified the survival probability at a landmark time point x = 2. The survival probability under the null and alternative was set to S 0 (2) = 0.2 − 0.6 and under the alternative was set to S 1 (2) = 0.2 − 0.75; the cure rate under the null was set to π 0 = 0 − 0.3 and under the alternative was set to π 1 = 0 − 0.45. We assumed that subjects were recruited with a uniform distribution over the accrual period t a = Wu Page 6
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3 and were followed for t f = 1. The censoring distribution is a uniform distribution on the interval [t f , t a + t f ]. Thus under any one of these survival distributions and the uniform censoring distribution, quantities υ 0 , υ 1 , υ 00 , and υ 01 can be calculated by numeric integrations.
Three scenarios of the alternative hypotheses were considered in the simulations. Scenario 1: improvements are in the short-term survival but not in the cure rate. Scenario 2: improvements are in the cure rate but not in the short-term survival. Scenario 3: improvements are in both the cure rate and short-term survival. Therefore, given the nominal significance level 0.05 and power of 80%, the required sample sizes for each parameter configuration, survival distribution and hypothesis scenario were calculated. The empirical type I error and power for the corresponding sample size were simulated based on 100,000 runs (Tables 1-3 ).
The simulation results can be summarized as follows. First, from sample size calculations, we observed that the sample sizes were in the typical range of a phase II trial for various designs and three hypotheses scenarios. Second, the empirical powers were close to the nominal level of 80%. Thus, the sample sizes were correctly estimated. The empirical type I errors were, in general, also close to the nominal level of 5%. Overall, the results showed that the one-sample test preserved type I error well and provided adequate power for designing single-arm phase II survival trials under the parametric cure models.
An Example
In this section, we illustrate the application of the study design, under a parametric cure model by using the data from the Eastern Cooperative Oncology Group (ECOG) trial e1684 as an example. The ECOG trial e1684 was a two-arm phase III clinical trial to compare the relapse-free survival (RFS) of patients with melanoma who were treated with high-dose interferon alpha-2b and placebo as postoperative adjuvant therapy. Researchers have extensively studied this dataset using the cure models [14] . There were 92 deaths among 146 patients in the treatment group. The SAS macro PSPMCM was applied to this data to fit the treatment arm data under the Weibull cure model (Figure) , with an estimated shape parameter κ = 1.018, scale parameter λ = 0.836, and cure rate of 35%. Suppose a new therapy is available, and we want to design a single-arm phase II study to compare the RFS of the new treatment to that of the treatment arm of the ECOG trial, which will serve as a literature control. Three scenarios are considered here: 1) improve the short-term survival by reducing the hazard rate 1.75 times but not the cure rate; 2) increase the cure rate by 20% but not the short-term survival; 3) increase the cure rate by 10% and improve the short-term survival by reducing the hazard rate 1.25 times. With a type I error of 0.05, power of 80% at the alternative, 3 years accrual period and 1 year follow-up, the required sample sizes calculated using formula (15) under the Weibull cure model are 93, 94 and 95 patients for scenarios 1-3, respectively. The corresponding simulated empirical type I error and power are 0.053 and 79.7%, 0.053 and 80%, and 0.054 and 79.6% for scenarios 1-3, respectively. Thus, the calculated sample sizes preserve the type I error and provide adequate power for the trial designs.
Conclusion
In this article, a sample size formula is derived for designing single-arm phase II trials under the parametric cure models. Three parametric cure models are considered, including the Weibull, Log-normal, Log-logistic distributions that have been implemented in a SAS macro PSPMCM. Thus, we can estimate the cure rate and model parameters by using the SAS macro for the trial design. The extensive simulations showed that the proposed test preserves type I error well and provides adequate power for the study design. Finally, the proposed method does not limit to the three cure models mentioned above; it can be applied to other parametric cure model too, such as the Gamma and Gompertz models, etc. Therefore, the proposed method has a wide range of applications for designing single-arm phase II trials under various parametric cure models. For convenience, two R functions SIZE and TEST are given (Appendix 2) for the sample size and p-value calculations using the proposed methods under the Weibull cure model. One can easily change the distribution in the R functions for trial designs under the Log-normal and Log-logistic distributions.
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Appendix 1: Derivation of the exact variance of W under the alternative
First, we calculate the mean and variance of W under the null hypothesis H 0 by noting that E H 0 (O) = nE H 0 (Δ) and .
Let
, and be the density, survival, and cumulative hazard functions of failure time T under the null and g(t) and G(t) be the density and survival functions of censoring time C. Then, by exchange of integrations, we have Let be the survival distribution of X = T ∧ C under the null, then and by integration by parts, we have b=pi1+(1−pi1)*exp(−lambda1*t^kappa); ans=a/b; return(ans)} f0=function(t){ans=G(t)*S1(t)*h0(t);return(ans)} f1=function(t){ans=G(t)*S1(t)*h1(t);return(ans)} f2=function(t){ans=G(t)*S1(t)*h0(t)*Lambda0(t);return(ans)} f3=function(t){ans=G(t)*S1(t)*h1(t)*Lambda0(t);return(ans)} tau=ta+tf # tau is the study duration z0=qnorm(1−alpha); z1=qnorm ( Table 1 Scenario 1 in which sample size, simulated empirical type I error (α), and power (1 − β)
were based on 100,000 simulation runs for various distributions.
The nominal type I error was 0.05 and power was 80%; the censoring distribution was uniform on [t Table 2 Scenario 2 in which sample size, simulated empirical type I error (α), and power (1 − β)
The nominal type I error was 0.05 and power was 80%; the censoring distribution was uniform on [t Abbreviations: Dist., distribution; LG, log-logistic; LN, log-normal; WB, Weibull.
